Medicalgorithmics received a CE certificate for its AI-based DeepRhythmAI (DRAI) algorithms for ECG analysis, previously approved by the FDA in 2022. The CE certification allows the company to introduce DRAI to European markets, enhancing its position in arrhythmia diagnostics. COO Jarosław Jerzakowski highlighted this as part of the company's strategy to boost sales.
Founded in 2005, Medicalgorithmics operates in the U.S. and Asia and has been listed on the main market of the Warsaw Stock Exchange since 2014, part of the sWIG80 index.
(ISBnews)